DETAILED NOTES ON 1986SHANTHA

Dr. Varaprasad regarded that pricey multinational recombinant vaccines experienced minimum market place penetration, and had not tapped into the entire potential of the vaccine. He recognized that he could leverage India's homegrown experts, the lower cost of labor, process innovation, and a low-margins business technique to exploit this opportunit